MY 014
Alternative Names: MY-014Latest Information Update: 29 Aug 2024
At a glance
- Originator Wuhan Createrna Science and Technology
- Class Anti-inflammatories; Skin disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 29 Aug 2024 Discontinued - Preclinical for Atopic dermatitis in China (unspecified route) before August 2024 (Wuhan Createrna Science and Technology pipeline, August 2024)
- 23 Oct 2023 Preclinical trials in Atopic dermatitis in China (unspecified route) prior to October 2023 (Wuhan Createrna Science and Technology pipeline, October 2023)